Erythrokeratodermia symmetrica progressiva

Erythrokeratodermia Symmetrica Progressiva (ESP) is a rare genetic disorder characterized by the presence of well-demarcated erythematous plaques and progressive symmetric hyperkeratosis. This condition falls under the broader category of erythrokeratodermias, which are disorders affecting the skin's ability to keratinize properly, leading to the development of red, scaly patches. ESP is distinguished by its pattern of symmetry and progression, as well as its genetic underpinnings.

Etiology and Genetics

ESP is primarily inherited in an autosomal dominant manner, meaning a single copy of the altered gene in each cell is sufficient to cause the disorder. The condition has been linked to mutations in the GJB3 gene, which encodes for connexin 31, a protein crucial for cell-to-cell communication in the skin. These mutations disrupt the normal function of connexin 31, leading to the characteristic symptoms of ESP.

Clinical Features

Individuals with ESP typically present with the condition in infancy or early childhood. The hallmark features include:

• Erythematous plaques: Red, inflamed patches that are well-demarcated and can appear anywhere on the body, but have a predilection for the limbs and buttocks.
• Hyperkeratosis: Thickening of the stratum corneum (the outermost layer of the skin) leading to scaly, rough patches that are symmetrically distributed.
• Progression: While the erythematous plaques may wax and wane, the hyperkeratotic areas tend to be persistent and can progress over time.

Diagnosis

Diagnosis of ESP is primarily clinical, based on the characteristic appearance of the skin lesions and their distribution. Genetic testing can confirm a diagnosis by identifying a mutation in the GJB3 gene. Histopathological examination of a skin biopsy may also aid in diagnosis, showing features such as hyperkeratosis and acanthosis.

Treatment

There is no cure for ESP, and treatment is aimed at managing symptoms and improving the quality of life for affected individuals. Therapeutic strategies may include:

• Emollients and keratolytics: To moisturize the skin and reduce scaling.
• Topical retinoids: To normalize keratinocyte differentiation and proliferation.
• Systemic retinoids: For severe cases, oral retinoids may be prescribed to reduce keratin production and improve skin appearance.

Prognosis

The prognosis for individuals with ESP is generally good, with most able to lead normal, healthy lives. However, the condition can be cosmetically disfiguring and may cause psychological distress. Regular follow-up with a dermatologist is recommended to monitor the skin and adjust treatment as necessary.

Erythrokeratodermia symmetrica progressiva Resources
Latest articles Most recent articles Ongoing trials	Wikipedia